These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

539 related items for PubMed ID: 1490728

  • 1. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
    Maas RA, Roest PA, Becker MJ, Weimar IS, Dullens HF, Den Otter W.
    Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
    [Abstract] [Full Text] [Related]

  • 2. Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2.
    Maas RA, Dullens HF, De Jong WH, Den Otter W.
    Cancer Res; 1989 Dec 15; 49(24 Pt 1):7037-40. PubMed ID: 2582444
    [Abstract] [Full Text] [Related]

  • 3. Transfer of tumor immunity by both CD4+ and CD8+ tumor infiltrating T lymphocytes activated in vivo by IL-2 therapy of tumor bearing mice.
    Maas RA, Becker MJ, Weimar IS, De Nooy JC, Dullens HF, Den Otter WD.
    Immunobiology; 1993 Jul 15; 188(3):281-92. PubMed ID: 7901148
    [Abstract] [Full Text] [Related]

  • 4. Combination immunotherapy of the P815 murine mastocytoma with killer cells, IL-2 and anti-estrogens.
    Baral E, Nagy E, Kangas L, Berczi I.
    Anticancer Res; 1997 Jul 15; 17(5A):3653-8. PubMed ID: 9413218
    [Abstract] [Full Text] [Related]

  • 5. Anti-estrogens potentiate the immunotherapy of the P815 murine mastocytoma by cytotoxic T lymphocytes.
    Nagy E, Baral E, Kangas L, Berczi I.
    Anticancer Res; 1997 Jul 15; 17(2A):1083-8. PubMed ID: 9137453
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S, Yamamoto H, Fujii Y, Arai S.
    Cancer Res; 1986 Nov 15; 46(11):5548-52. PubMed ID: 2428480
    [Abstract] [Full Text] [Related]

  • 7. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P, De Meyer M, Leroy P, Rousseau C, Acres B.
    Cancer Gene Ther; 2001 May 15; 8(5):321-32. PubMed ID: 11477452
    [Abstract] [Full Text] [Related]

  • 8. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M, Orosz CG, Bach FH.
    J Immunol; 1984 Jun 15; 132(6):3218-25. PubMed ID: 6202778
    [Abstract] [Full Text] [Related]

  • 9. Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization.
    Bour H, Horvath C, Lurquin C, Cerottini JC, MacDonald HR.
    J Immunol; 1998 Jun 01; 160(11):5522-9. PubMed ID: 9605156
    [Abstract] [Full Text] [Related]

  • 10. Studies on the minimum requirements for in vitro "cure" of tumor cells by cytotoxic T lymphocytes.
    Miki S, Ksander B, Streilein JW.
    Reg Immunol; 1992 Jun 01; 4(6):352-62. PubMed ID: 1297406
    [Abstract] [Full Text] [Related]

  • 11. Specific tumoricidal activity of cytotoxic macrophages and cytotoxic lymphocytes.
    Dullens HF, Schakenraad S, Oostdijk A, Vuist W, Van der Maas M, Den Otter W.
    Cancer Immunol Immunother; 1986 Jun 01; 22(2):100-6. PubMed ID: 3487380
    [Abstract] [Full Text] [Related]

  • 12. The immunologic function of 1B2+ double negative (CD4-CD8-) T cells in the 2C transgenic mouse.
    Margenthaler JA, Flye MW.
    J Surg Res; 2005 Jun 15; 126(2):160-6. PubMed ID: 15919414
    [Abstract] [Full Text] [Related]

  • 13. Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones.
    Engers HD, Lahaye T, Sorenson GD, Glasebrook AL, Horvath C, Brunner KT.
    J Immunol; 1984 Sep 15; 133(3):1664-70. PubMed ID: 6205090
    [Abstract] [Full Text] [Related]

  • 14. Mechanisms of tumor regression induced by low doses of interleukin-2.
    Maas RA, Dullens HF, Den Otter W.
    In Vivo; 1991 Sep 15; 5(6):637-41. PubMed ID: 1810449
    [Abstract] [Full Text] [Related]

  • 15. Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.
    Ley V, Langlade-Demoyen P, Kourilsky P, Larsson-Sciard EL.
    Eur J Immunol; 1991 Mar 15; 21(3):851-4. PubMed ID: 2009918
    [Abstract] [Full Text] [Related]

  • 16. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
    Tomita Y, Mayumi H, Eto M, Nomoto K.
    J Immunol; 1990 Mar 15; 144(6):2425-35. PubMed ID: 1968930
    [Abstract] [Full Text] [Related]

  • 17. Effective immunotherapy with local low doses of interleukin-2.
    Den Otter W, Maas RA, Koten JW, Dullens HF, Bernsen M, Klein WR, Rutten VP, Steerenberg PA, Balemans L, Ruitenberg EJ.
    In Vivo; 1991 Mar 15; 5(6):561-5. PubMed ID: 1810439
    [Abstract] [Full Text] [Related]

  • 18. Differential development of CD4 and CD8 cytotoxic T cells (CTL) in PBMC across the leprosy spectrum; IL-6 with IFN-gamma or IL-2 generate CTL in multibacillary patients.
    de la Barrera S, Finiasz DM, Fink S, Valdez R, Bottasso O, Balina LM, Sasiain MC.
    Int J Lepr Other Mycobact Dis; 1997 Mar 15; 65(1):45-55. PubMed ID: 9207753
    [Abstract] [Full Text] [Related]

  • 19. Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells.
    Loeffler CM, Smyth MJ, Longo DL, Kopp WC, Harvey LK, Tribble HR, Tase JE, Urba WJ, Leonard AS, Young HA.
    J Immunol; 1992 Aug 01; 149(3):949-56. PubMed ID: 1353099
    [Abstract] [Full Text] [Related]

  • 20. Development of CD8+ effector T cells is differentially regulated by IL-18 and IL-12.
    Okamoto I, Kohno K, Tanimoto T, Ikegami H, Kurimoto M.
    J Immunol; 1999 Mar 15; 162(6):3202-11. PubMed ID: 10092771
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.